Results 91 to 100 of about 18,669 (233)

Medical conditions associated with Prolonged Activated Partial Thromboplastin time in Swat

Gomal Journal of Medical Sciences, 2010
Background: APPT is a commonly requested laboratory test in various bleeding conditions and as a screening test preoperatively. It is also used to monitor heparin therapy.
Mukamil Shah, Imran ud Din Khattak, Sania Tanweer Khattak, Ahad Abdul, Muhammad Amin Jan Mahsud   +4 more
doaj  

Association of factor expression levels with annual bleeding rate in people with haemophilia B. [PDF]

Haemophilia, 2023
Burke T, Shaikh A, Ali TM, Li N, Konkle BA, Noone D, O'Mahony B, Pipe S, O'Hara J.   +8 more
europepmc   +1 more source

DDAVP Challenges in 170 Children With von Willebrand Disease: Response Classification Varies According to Criteria Used

Haemophilia, EarlyView.
ABSTRACT Introduction Individuals diagnosed with types 1/1C/2A/2M von Willebrand disease (VWD) typically undergo a desmopressin (DDAVP) challenge to assess therapeutic benefit. This involves measuring von Willebrand factor antigen (VWF:Ag), activity (VWF:Act; VWF:RCo/VWF:GPIbM/VWF:Ab), and coagulant factor VIII (FVIII:C) levels 0 (pre), 1, and 4‐h post‐
Michael Shu, Caroline Malcolmson, Amanda Fregonas, Tristan E. Knight, Margaret L. Rand, Cindy Wakefield, Vanessa Bouskill, Manuel Carcao   +7 more
wiley   +1 more source

Physical activity patterns in people with haemophilia with and without arthropathy: a cross-sectional study using wearable sensors

Thrombosis Journal
Background In haemophilia, recurrent joint bleeding often results in joint destruction, which in turn leads to reduced physical activity (PA) and decreased quality of life (QOL).
Yuya Mawarikado, Midori Shima, Naoki Matsumoto, Asuka Sakata, Ryohei Kawasaki, Kohei Tatsumi, Tetsuhiro Soeda, Suguru Harada, Naoto Seriu, Yusuke Inagaki, Akira Kido, Keiji Nogami   +11 more
doaj   +1 more source

Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries. [PDF]

Adv Ther, 2023
Funding E, Lowe G, Poulsen LH, Shapiro S, Oldenburg J, Eriksson D, Falk A, Rich C.   +7 more
europepmc   +1 more source

Global Diagnostics of Hemophilia and Bleeding Disorders: Insights From World Federation of Hemophilia International External Quality Assessment Scheme Program 2016–2023

Haemophilia, EarlyView.
ABSTRACT Introduction Accurate laboratory diagnosis is essential for the effective management of bleeding disorders. The World Federation of Hemophilia (WFH) International External Quality Assessment Scheme (IEQAS) provides an international platform for comparative evaluation of laboratory performance.
Silmara de Lima Montalvão, Ian Jennings, Dianne P. Kitchen, Christopher Reilly‐Stitt, Glenn F. Pierce, Andreina Tovar, Jayson Martin, Assad Haffar, Steve Kitchen   +8 more
wiley   +1 more source

TREATMENT SATISFACTION AND JOINT HEALTH OUTCOMES WITHIN A REAL-WORLD HAEMOPHILIA B POPULATION: THE ADELPHI DISEASE SPECIFIC PROGRAMMESURVEY

Hematology, Transfusion and Cell Therapy
Background: While haemophilia care continues to improve, People with Haemophilia B (PwHB) may still experience disease and treatment burden. Aims: To describe physician-reported treatment satisfaction and joint health outcomes in a real-world population ...
V Jiméne-ZYuste, C Percier, T Porstmann, N Ball, G Castaman, GG Fabbron, MGA Okuma   +6 more
doaj   +1 more source

Factor IX Padua for haemophilia B gene addition: universal adaptation and repeated success. [PDF]

Lancet Haematol, 2022
George LA.
europepmc   +1 more source

Real‐World Experience With Emicizumab for Haemophilia A From the Physician Perspective in a Real‐World Clinical Setting

Haemophilia, EarlyView.
ABSTRACT Introduction Emicizumab is a bispecific antibody approved for prophylaxis in people with haemophilia A (PwHA). Aim To describe from the physician perspective the characteristics and treatment experiences of PwHA receiving emicizumab. Methods The Adelphi Real World Haemophilia Disease Specific Programme is a cross‐sectional, retrospective data ...
Michael Recht, Chris Blazos, Sophie Lai, Nathan Ball, Ella Morton, Lucy Lee, Juliana M. L. Biondo, Janet S. Lee   +7 more
wiley   +1 more source

Mutation analysis and characterisation of F9 gene in haemophilia- B population of India. [PDF]

Blood Res, 2021
Kulkarni S, Hegde R, Hegde S, Kulkarni SS, Hanagvadi S, Das KK, Kolagi S, Gai PB, Bulagouda R.   +8 more
europepmc   +1 more source